Voyager Therapeutics (NASDAQ:VYGR) Downgraded by Wall Street Zen to “Sell”

Voyager Therapeutics (NASDAQ:VYGR) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Other equities analysts have also recently issued reports about the company. Wedbush restated an “outperform” rating and set a $8.00 price target on shares of Voyager Therapeutics in a report on Tuesday, November 11th. HC Wainwright lowered their price objective on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, November 12th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.75.

Voyager Therapeutics Price Performance

Shares of Voyager Therapeutics stock opened at $3.49 on Friday. The stock’s 50-day moving average is $3.89 and its 200 day moving average is $4.09. Voyager Therapeutics has a one year low of $2.64 and a one year high of $5.55. The firm has a market cap of $194.04 million, a price-to-earnings ratio of -1.62 and a beta of 1.30.

Insider Activity at Voyager Therapeutics

In other news, CEO Alfred Sandrock sold 12,192 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $3.78, for a total transaction of $46,085.76. Following the completion of the sale, the chief executive officer owned 509,989 shares in the company, valued at $1,927,758.42. The trade was a 2.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold a total of 20,286 shares of company stock worth $77,248 in the last ninety days. Insiders own 6.39% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

A number of large investors have recently modified their holdings of the company. AQR Capital Management LLC increased its stake in Voyager Therapeutics by 179.3% during the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock valued at $1,674,000 after purchasing an additional 317,927 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Voyager Therapeutics in the first quarter valued at $218,000. Acadian Asset Management LLC grew its holdings in shares of Voyager Therapeutics by 863.3% during the first quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock valued at $778,000 after buying an additional 206,758 shares during the last quarter. Ethic Inc. bought a new stake in shares of Voyager Therapeutics during the second quarter worth about $123,000. Finally, R Squared Ltd bought a new stake in shares of Voyager Therapeutics during the second quarter worth about $48,000. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.